PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS

被引:0
|
作者
Tillie, R. [1 ]
De Bruijn, J. [1 ]
Dobie, R. [2 ]
Perales-Paton, J. [3 ]
Van Kuijk, K. [1 ]
Gijbels, M. [1 ]
Temmerman, L. [1 ]
Ghosheh, Y. [4 ]
Goossens, G. [5 ]
Carmeliet, P. [6 ]
Ley, K. [4 ]
Henderson, N. [2 ]
Saez-Rodriguez, J. [3 ]
Wouters, K. [7 ]
Sluimer, J. [1 ]
机构
[1] Maastricht Univ, Pathol, Med Ctr, Maastricht, Netherlands
[2] Univ Edinburgh, Mrc Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[3] Heidelberg Univ, Inst Computat Biomed, Heidelberg, Germany
[4] La Jolla Inst Immunol, Ctr Autoimmun & Inflammat, San Diego, CA USA
[5] Maastricht Univ, Human Biol, Maastricht, Netherlands
[6] Katholieke Univ Leuven, Lab Angiogenesis & Vasc Metab, Leuven, Belgium
[7] Maastricht Univ, Internal Med, Maastricht, Netherlands
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
O079
引用
收藏
页数:2
相关论文
共 11 条
  • [1] Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Angiogenesis
    Abdali, Anahita
    Corsini, Alberto
    Baci, Denisa
    De Dominicis, Carlo
    Zanda, Matteo
    Gelmi, Maria Luisa
    Bellosta, Stefano
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [2] ANGIOGENESIS INHIBITION WITH NOVEL COMPOUNDS TARGETING THE KEY GLYCOLYTIC ENZYME PFKFB3
    Abdali, A.
    Corsini, A.
    Baci, D.
    De Dominicis, C.
    Zanda, M.
    Gelmi, M. L.
    Bellosta, S.
    [J]. ATHEROSCLEROSIS, 2018, 275 : E127 - E127
  • [3] Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Angiogenesis
    Abdali, Anahita
    Corsini, Alberto
    Baci, Denisa
    De Dominicis, Carlo
    Zanda, Matteo
    Gelmi, Maria Luisa
    Bellosta, Stefano
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [4] In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3
    Abdali, Anahita
    Baci, Denisa
    Damiani, Isabella
    Belloni, Federica
    De Dominicis, Carlo
    Gelmi, Maria Luisa
    Corsini, Alberto
    Bellosta, Stefano
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 168
  • [5] Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
    Tillie, Renee J. H. A.
    De Bruijn, Jenny
    Perales-Paton, Javier
    Temmerman, Lieve
    Ghosheh, Yanal
    Van Kuijk, Kim
    Gijbels, Marion J.
    Carmeliet, Peter
    Ley, Klaus
    Saez-Rodriguez, Julio
    Sluimer, Judith C.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [6] Partial Inhibition of the Key Glycolytic Enzyme PFKFB3 in Myeloid Cells Impacts Whole-Body Immune Cell and Liver Metabolism, But Not Atherogenesis
    de Bruijn, Jenny
    van Kuijk, Kim
    Bijnen, Mitchell
    Sander, Bianca
    Gijbels, Marion
    Carmeliet, Peter
    Wouters, Kristiaan
    Sluimer, Judith C.
    [J]. JOURNAL OF VASCULAR RESEARCH, 2019, 56 : 24 - 24
  • [7] Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
    Tillie, Renee J. H. A.
    De Bruijn, Jenny
    Perales-Paton, Javier
    Temmerman, Lieve
    Ghosheh, Yanal
    Van Kuijk, Kim
    Gijbels, Marion J.
    Carmeliet, Peter
    Ley, Klaus
    Saez-Rodriguez, Julio
    Sluimer, Judith C.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [8] PARTIAL INHIBITION OF THE KEY GLYCOLYTIC ENZYME PFKFB3 IN MYELOID CELLS IMPACTS WHOLE-BODY IMMUNE CELL AND LIVER METABOLISM, BUT NOT ATHEROGENESIS.
    De Bruijn, J.
    van Kuijk, K.
    Bijnen, M.
    Gijbels, M.
    Wouters, K.
    Carmeliet, P.
    Sluimer, J.
    [J]. ATHEROSCLEROSIS, 2019, 287 : E19 - E20
  • [9] Disruption of Myeloid Cell-Specific PFKFB3 Exacerbates Diet-Induced Hepatic Steatosis and Inflammation in Mice
    Li, Honggui
    Ma, Linqiang
    Zhou, Jing
    Luo, Xianjun
    Francis, Heather L.
    Glaser, Shannon
    Meng, Fanyin
    Alpini, Gianfranco
    Wu, Chaodong
    [J]. HEPATOLOGY, 2018, 68 : 732A - 732A
  • [10] Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3)
    Brooke, Darby G.
    van Dam, Ellen M.
    Watts, Colin K. W.
    Khoury, Amanda
    Dziadek, Marie A.
    Brooks, Hilary
    Graham, Lisa-Jane K.
    Flanagan, Jack U.
    Denny, William A.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (03) : 1029 - 1039